Skip to main navigation Skip to search Skip to main content

Pontocerebellar hypoplasia type 1: Clinical spectrum and relevance of EXOSC3 mutations

  • Sabine Rudnik-Schöneborn
  • , Jan Senderek
  • , Joanna C. Jen
  • , Gunnar Houge
  • , Pavel Seeman
  • , Alena Puchmajerová
  • , Luitgard Graul-Neumann
  • , Ulrich Seidel
  • , Rudolf Korinthenberg
  • , Janbernd Kirschner
  • , J. rgen Seeger
  • , Monique M. Ryan
  • , Francesco Muntoni
  • , Maja Steinlin
  • , Laszlo Sztriha
  • , Jaume Colomer
  • , Christoph Hübner
  • , Knut Brockmann
  • , Lionel van Maldergem
  • , Manuel Schiff
  • Andreas Holzinger, Peter Barth, William Reardon, Michael Yourshaw, Stanley F. Nelson, Thomas Eggermann, Klaus Zerres
  • RWTH Aachen University
  • Ludwig Maximilian University of Munich
  • University of California at Los Angeles
  • University of Bergen
  • Charles University
  • Charité – Universitätsmedizin Berlin
  • University of Freiburg
  • Deutsche Klinik für Diagnostik
  • University of Melbourne
  • NIHR Great Ormond Street Biomedical Research Centre, London, UK
  • University Children’s Hospital Bern, Inselspital, University of Bern, Switzerland.
  • University of Szeged
  • SJD Barcelona Children's Hospital
  • University of Göttingen
  • Université de Franche-Comté
  • Hôpital Robert Debré AP-HP
  • University of Amsterdam
  • Our Lady's Hospital for Sick Children

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Objectives: Pontocerebellar hypoplasia with spinal muscular atrophy, also known as PCH1, is a group of autosomal recessive disorders characterized by generalized muscle weakness and global developmental delay commonly resulting in early death. Gene defects had been discovered only in single patients until the recent identification of EXOSC3 mutations in several families with relatively mild course of PCH1.We aim to genetically stratify subjects in a large and well-defined cohort to define the clinical spectrum and genotypephenotype correlation. Methods: We documented clinical, neuroimaging, and morphologic data of 37 subjects from 27 families with PCH1. EXOSC3 gene sequencing was performed in 27 unrelated index patients of mixed ethnicity. Results: Biallelic mutations in EXOSC3 were detected in 10 of 27 families (37%). The most common mutation among all ethnic groups was c.395A>C, p.D132A, responsible for 11 (55%) of the 20 mutated alleles and ancestral in origin. The mutation-positive subjects typically presented with normal pregnancy, normal birth measurements, and relative preservation of brainstemand cortical structures. Psychomotor retardation was profound in all patients but lifespan was variable, with 3 subjects surviving beyond the late teens. Abnormal oculomotor function was commonly observed in patients surviving beyond the first year. Major clinical features previously reported in PCH1, including intrauterine abnormalities, postnatal hypoventilation and feeding difficulties, joint contractures, and neonatal death,were rarely observed inmutation-positive infants but were typical among themutation-negative subjects. Conclusion: EXOSC3 mutations account for 30%-40% of patients with PCH1 with variability in survival and clinical severity that is correlated with the genotype. © 2013 American Academy of Neurology.
Original languageEnglish
Pages (from-to)438-446
JournalNeurology
Volume80
Issue number5
DOIs
Publication statusPublished - 29 Jan 2013
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Pontocerebellar hypoplasia type 1: Clinical spectrum and relevance of EXOSC3 mutations'. Together they form a unique fingerprint.

Cite this